Sublingual five-grass pollen tablets (Oralair^®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis

Abstract

Sublingual 300 IR five-grass pollen allergen extract tablets (Oralair^®) are a valuable option in patients with grass-pollen induced allergic rhinoconjunctivitis. Allergen immunotherapy with sublingual five-grass pollen tablets beginning 4 months before and continuing throughout the grass pollen season reduces the symptoms of allergic rhinoconjunctivitis and the use of symptomatic rescue medications during the pollen season. Precautions should be followed to minimize the risk of systemic and local allergic reactions that may occur with allergen immunotherapy.